EP0859771A4 - SUBSTITUTED PYRIDYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHOD OF USE - Google Patents

SUBSTITUTED PYRIDYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHOD OF USE

Info

Publication number
EP0859771A4
EP0859771A4 EP96942022A EP96942022A EP0859771A4 EP 0859771 A4 EP0859771 A4 EP 0859771A4 EP 96942022 A EP96942022 A EP 96942022A EP 96942022 A EP96942022 A EP 96942022A EP 0859771 A4 EP0859771 A4 EP 0859771A4
Authority
EP
European Patent Office
Prior art keywords
compounds
compositions containing
substituted pyridyl
pyrroles
pyridyl pyrroles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96942022A
Other languages
German (de)
French (fr)
Other versions
EP0859771A1 (en
Inventor
Laszlo Stephen E De
Linda L Chang
Dooseop Kim
Nathan B Mantlo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605158.6A external-priority patent/GB9605158D0/en
Priority claimed from GBGB9612062.1A external-priority patent/GB9612062D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0859771A1 publication Critical patent/EP0859771A1/en
Publication of EP0859771A4 publication Critical patent/EP0859771A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP96942022A 1995-10-31 1996-10-30 SUBSTITUTED PYRIDYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHOD OF USE Withdrawn EP0859771A4 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US710095P 1995-10-31 1995-10-31
US7100P 1995-10-31
GBGB9605158.6A GB9605158D0 (en) 1996-03-12 1996-03-12 Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
GB9605158 1996-03-12
US1556596P 1996-04-18 1996-04-18
US15565 1996-04-18
GBGB9612062.1A GB9612062D0 (en) 1996-06-10 1996-06-10 Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
GB9612062 1996-06-10
PCT/US1996/018539 WO1997016442A1 (en) 1995-10-31 1996-10-30 Substituted pyridyl pyrroles, compositions containing such compounds and methods of use

Publications (2)

Publication Number Publication Date
EP0859771A1 EP0859771A1 (en) 1998-08-26
EP0859771A4 true EP0859771A4 (en) 2000-03-15

Family

ID=27451424

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96942022A Withdrawn EP0859771A4 (en) 1995-10-31 1996-10-30 SUBSTITUTED PYRIDYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHOD OF USE

Country Status (4)

Country Link
EP (1) EP0859771A4 (en)
JP (1) JPH11514651A (en)
AU (1) AU702887B2 (en)
WO (1) WO1997016442A1 (en)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
BR9710352A (en) * 1996-07-11 1999-08-17 Pfizer Pyridylpyrrole compounds
DE69728688T2 (en) 1996-11-19 2004-08-19 Amgen Inc., Thousand Oaks ARYL AND HETEROARYL SUBSTITUTED CONDENSED PYRROLE AS AN ANTI-FLAMMING AGENT
EP1314732A3 (en) * 1996-12-05 2004-01-02 Amgen Inc. Substituted pyrimidine compounds and their use
AR038955A1 (en) * 1996-12-05 2005-02-02 Amgen Inc PIRIMIDINONE AND PIRIDONA SUBSTITUTED COMPOUNDS AND METHODS FOR USE
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
IL130181A0 (en) * 1996-12-05 2000-06-01 Amgen Inc Substituted pyrimidone and pyridone compounds and methods of use
KR100704059B1 (en) 1997-06-12 2007-04-05 롱프랑 로라 리미티드 Imidazolyl-cyclic acetal
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU749271B2 (en) * 1997-07-01 2002-06-20 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
EP1473292A1 (en) * 1997-11-03 2004-11-03 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
WO1999023091A1 (en) * 1997-11-03 1999-05-14 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
ATE295166T1 (en) * 1998-01-14 2005-05-15 Nippon Shinyaku Co Ltd ACTIVATORS OF POTASSIUM CHANNELS
US6232322B1 (en) 1998-05-12 2001-05-15 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
JP2002514635A (en) * 1998-05-12 2002-05-21 アメリカン・ホーム・プロダクツ・コーポレイション Biphenyloxo-acetic acid useful for treating insulin resistance and hyperglycemia
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
CA2346665A1 (en) 1998-10-07 2000-04-13 Smithkline Beecham Corporation Novel treatment for stroke management
DE19847823A1 (en) * 1998-10-16 2000-04-20 Aventis Pharma Gmbh New 3-(Hetero)aryl-5-aminosulfonyl-1,2,4-thiadiazole derivatives useful as inhibitors of IL-1beta production in treatment of e.g. leukemia, septic shock, hepatitis, AIDS and diseases of locomotor system
WO2000025791A1 (en) 1998-11-04 2000-05-11 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
WO2000055152A1 (en) 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
WO2000066124A1 (en) * 1999-04-28 2000-11-09 Sankyo Company, Limited Preventive or inhibitory agents for hepatopathy
US6310081B1 (en) 1999-05-10 2001-10-30 American Home Products Corporation Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
WO2000069847A1 (en) * 1999-05-14 2000-11-23 Ortho-Mcneil Pharmaceutical, Inc. Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
ATE312823T1 (en) 1999-07-09 2005-12-15 Boehringer Ingelheim Pharma METHOD FOR PRODUCING HETEROARYL-SUBSTITUTED UREA COMPOUNDS
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
CA2384782A1 (en) 1999-09-14 2001-03-22 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
US6900043B1 (en) 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
WO2001032658A1 (en) * 1999-11-02 2001-05-10 Ajinomoto Co., Inc. Polyazanaphthalene compound and medicinal use thereof
WO2001036403A1 (en) 1999-11-16 2001-05-25 Boehringer Ingelheim Pharmaceuticals, Inc. Urea derivatives as anti-inflammatory agents
ATE305787T1 (en) 1999-11-23 2005-10-15 Smithkline Beecham Corp 3,4-DIHYDRO-(1H)CHINAZOLINE-2-ONE COMPOUNDS AS CSBP/P39 KINASE INHIBITORS
EP1233951B1 (en) 1999-11-23 2005-06-01 SmithKline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
PT1741446E (en) 2000-01-21 2008-05-09 Novartis Pharma Ag Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
JP2004513935A (en) 2000-11-17 2004-05-13 ノボ　ノルディスク　アクティーゼルスカブ Glucagon antagonist / inverse agonist
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
CA2435141A1 (en) * 2001-01-18 2002-07-25 Sankyo Company, Limited Compositions for prevention or treatment of hepatopathy
WO2002057255A1 (en) * 2001-01-22 2002-07-25 Sankyo Company, Limited 4- or 5-substituted pyrrole derivatives
MY130778A (en) 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
WO2002092576A1 (en) 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
EP1395561A1 (en) 2001-05-25 2004-03-10 Boehringer Ingelheim Pharmaceuticals Inc. Carbamate and oxamide compounds as inhibitors of cytokine production
WO2003007955A2 (en) * 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
KR100896667B1 (en) * 2001-08-28 2009-05-14 레오 파마 에이/에스 Novel aminobenzophenones and pharmaceutical compositions comprising them
US7446106B2 (en) 2001-09-05 2008-11-04 Smithkline Beecham Plc Pyridylfurans and pyrroles as Raf kinase inhibitors
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
ATE386030T1 (en) 2002-02-25 2008-03-15 Boehringer Ingelheim Pharma 1,4-DISUBSTITUTED BENZOCONDENSED CYCLOALKYL-UREA COMPOUNDS FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES
DE60310730T2 (en) 2002-07-09 2007-05-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg PHARMACEUTICAL COMPOSITIONS OF ANTICHOLINERGICA AND P38 KINASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES
US20050043331A1 (en) * 2002-09-27 2005-02-24 Bullington James L. Substituted 3-(2,5-disubstituted)pyridyl-4-aryl pyrroles for treating inflammatory diseases
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
US7572922B2 (en) 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
CA2547785A1 (en) 2003-12-19 2005-07-21 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
DE602005006806D1 (en) 2004-06-04 2008-06-26 Merck & Co Inc Pyrazole derivatives, compositions containing such compounds, and methods of use
US7625938B2 (en) 2004-07-22 2009-12-01 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
US7803951B2 (en) 2005-03-30 2010-09-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2009502923A (en) 2005-07-26 2009-01-29 メルク エンド カムパニー インコーポレーテッド Method for the synthesis of substituted pyrazoles
PL1931350T5 (en) 2005-09-14 2021-11-15 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
KR20080064956A (en) 2005-09-27 2008-07-10 미리어드 제네틱스, 인크. Pyrrole Derivatives as Therapeutic Compounds
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
US7989472B2 (en) 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2038289A2 (en) 2006-04-21 2009-03-25 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
WO2007136577A2 (en) 2006-05-16 2007-11-29 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CA2656507C (en) 2006-07-17 2012-03-20 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
AU2007293065B2 (en) 2006-09-05 2011-08-18 Amgen Inc. Phthalazine, AZA- and diaza-phthalazine compounds and methods of use
BRPI0717097A2 (en) 2006-09-21 2013-11-26 Novartis Ag PIRROL DERIVATIVES USEFUL FOR TREATMENT OF CYTOKINE MEDIATED DISEASES
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2086973B1 (en) 2006-10-11 2012-01-25 Amgen Inc., Imidazo- and triazolo-pyridine compounds and methods of use therof
KR20090115749A (en) * 2007-02-26 2009-11-05 산텐 세이야꾸 가부시키가이샤 Novel pyrrole derivatives having ureide groups and aminocarbonyl groups as substituents
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
WO2009038784A1 (en) 2007-09-21 2009-03-26 Amgen Inc. Triazole fused heteroaryl compounds as p38 kinase inhibitors
US8455495B2 (en) 2008-08-29 2013-06-04 Amgen Inc. Pyridazino-pyridinone compounds and methods of use
EP2334673A1 (en) 2008-08-29 2011-06-22 Amgen Inc. PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
WO2010042649A2 (en) 2008-10-10 2010-04-15 Amgen Inc. PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF
US8772481B2 (en) 2008-10-10 2014-07-08 Amgen Inc. Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
PL2531501T3 (en) 2010-02-03 2014-05-30 Takeda Pharmaceuticals Co Apoptosis signal-regulating kinase 1 inhibitors
MX2013006768A (en) 2010-12-23 2013-07-22 Pfizer Glucagon receptor modulators.
HRP20161177T1 (en) 2011-02-08 2016-11-04 Pfizer Inc. Glucagon receptor modulator
AU2012288493B2 (en) 2011-07-22 2015-08-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
EP3065736B1 (en) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
IT201800003680A1 (en) * 2018-03-16 2019-09-16 Univ Degli Studi Di Siena ANTIVIRAL COMPOUNDS AND USES OF THEM

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2113861A1 (en) * 1970-11-16 1972-06-30 Pfizer
EP0034798A2 (en) * 1980-02-19 1981-09-02 E.I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-(substituted-thio)pyrroles and their corresponding sulfoxides and sulfones
WO1993014081A1 (en) * 1992-01-13 1993-07-22 Smithkline Beecham Corporation Imidazole derivatives and their use as cytokine inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267185A (en) * 1980-04-09 1981-05-12 E. I. Du Pont De Nemours And Company Antidepressant pyrrolylpiperidines, their pharmaceutical compositions and method of use
US4652582A (en) * 1985-01-09 1987-03-24 E. I. Du Pont De Nemours And Company Antiinflammatory-2-halo-4,5-diarylpyrroles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2113861A1 (en) * 1970-11-16 1972-06-30 Pfizer
EP0034798A2 (en) * 1980-02-19 1981-09-02 E.I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-(substituted-thio)pyrroles and their corresponding sulfoxides and sulfones
WO1993014081A1 (en) * 1992-01-13 1993-07-22 Smithkline Beecham Corporation Imidazole derivatives and their use as cytokine inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KONAKAHARA, TAKEO ET AL: "One-pot synthesis of pyrroles from N-silyl-1-azaallyl anions", HETEROCYCLES ( 1993 ), 35(2), 1171-84, 1993, XP000857214 *
See also references of WO9716442A1 *
SILVESTRI, G. ET AL: "Electrochemical oxidation of 2,4,5-triaryl-substituted pyrroles. II. Oxidative dimerization of 4,5-diphenyl-2-mesitylylpyrrole", J. HETEROCYCL. CHEM. ( 1989 ), 26(2), 489-92, 1989, XP000857212 *
SILVESTRI, G. ET AL: "Electrochemical oxidation of substituted pyrroles. IV. The influence of soluble bases", J. HETEROCYCL. CHEM. ( 1992 ), 29(7), 1847-50, 1992, XP000857213 *

Also Published As

Publication number Publication date
AU1120897A (en) 1997-05-22
WO1997016442A1 (en) 1997-05-09
AU702887B2 (en) 1999-03-11
EP0859771A1 (en) 1998-08-26
JPH11514651A (en) 1999-12-14

Similar Documents

Publication Publication Date Title
EP0859771A4 (en) SUBSTITUTED PYRIDYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHOD OF USE
EP0871444A4 (en) 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
EP0948257A4 (en) TRIARYL SUBSTITUTED IMIDAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
SI0807111T1 (en) Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same
PL323470A1 (en) Application of n-propargil-1-amidoindane (r)-enantionmer, its salts and compositions containing same
EP0746301A4 (en) SELF-TANNING COSMETIC COMPOSITIONS AND METHOD OF USING THE SAME
MA24158A1 (en) SUBSTITUTED IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM
FI940680A7 (en) Method for the preparation of compounds containing sulfamoyl and amidino groups
FR2703993B1 (en) Cosmetic use of lipophilic derivatives of amino deoxyalditols, cosmetic compositions containing them, and new alkyl carbamates.
FI972309L (en) 2-Heterocyclyloxy- and thiomethyl-1,2,5-thiadizolidin-3-one-1,1-dioxides, compositions containing them and method for their preparation
EP1015430A4 (en) SPIRO PYRROLIDINE-2,3'-OXINDOLE] COMPOUNDS AND METHODS OF USE
DE69124769D1 (en) Process for the preparation of (1'R, 3S) -3- (1'-hydroxy-ethyl) -azetidin-2-one and their derivatives
FI935825L (en) 2,4-substituted 5-(N-substituted-sulfamoyl)-benzoylguanidines, a process for their preparation, their use as a pharmaceutical or diagnostic agent, and a pharmaceutical containing them
FR2749504B1 (en) COMPOSITION OF SUSPENSION FOR A COSMETIC PRODUCT AND METHOD OF USING THE SAME
FR2731706B1 (en) AROMATIC HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM AND USES
EP0604024A3 (en) Reactive ink compositions and system.
FR2731151B1 (en) COLORING COMPOSITION FOR HAIR CONTAINING BALSAMINA IMPATIENT ROOT BROYAT, AND APPLICATION THEREOF
FR2730995B1 (en) BI-AROMATIC COMPOUNDS DERIVED FROM AMIDE, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM AND USES THEREOF
IL117808A (en) 1, 3-dihydro-1-(phenylalkenyl)- 2h-imidazol-2-one derivatives, their preparation and pharmaceutical compositions containing them
OA09749A (en) "1-aryl-5- (substituted alkylideneimino) -pyrazoles pesticides, processes for their preparation, compositions containing them and their use".
FI972306L (en) Substituted 2-arylcarbonyloxymethyl-1,2,5-thiadiazolidin-3-one-1,1-dioxide derivatives and compositions containing them and methods for using them
FR2732019B1 (en) PHOTOCHROMIC SPIROPYRANS, COMPOSITIONS AND ARTICLES CONTAINING THEM
EP0750620A4 (en) CARBAPENEMIC COMPOUNDS, COMPOSITIONS CONTAINING SAME, AND METHODS OF TREATMENT THEREOF
IL117806A (en) 1,3-dihydro-2H-imidazol-2-one derivatives their preparation and pharmaceutical compositions containing them
CA2112240C (en) Image-forming materials including color-providing compounds comprising two or more cyclic 1,3-sulfur-nitrogen groups and two or more color- providing moieties

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980602

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 401/04 A, 7A 61K 31/44 B, 7C 07D 403/04 B, 7C 07D 409/14 B, 7C 07D 407/14 B, 7C 07D 401/14 B, 7C 07D 413/14 B, 7C 07D 417/14 B, 7C 07D 401/04 J, 7C 07D 213:00 J, 7C 07D 207:00 J

A4 Supplementary search report drawn up and despatched

Effective date: 20000128

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20000823

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030510